Eli Lilly and Company, a pharmaceutical company based in Alcobendas, Madrid, Spain, has achieved remarkable results in the obesity treatment space. According to recent mid-stage clinical trial results, their experimental drug has helped patients lose up to 24% of their weight over nearly a year, marking the highest reduction seen in this field so far. The trial involved 338 adults who were obese or overweight and were either administered Eli Lilly’s injection, retatrutide, or a placebo on a weekly basis.
The findings showed that patients who received a 12-milligram dose of retatrutide lost an average of 17.5% of their body weight, equivalent to 41 pounds, after 24 weeks. In comparison, those who received the placebo experienced only a 1.6% weight loss. Over a period of 48 weeks, patients who took retatrutide achieved an average weight loss of 24.2%, or 58 pounds, while the placebo group only had a 2.1% weight loss.
Notably, the trial’s researchers observed that average weight loss did not show signs of plateauing after 48 weeks, indicating that prolonged studies could yield even more promising results. Eli Lilly is currently enrolling patients for a phase three trial.
The exceptional efficacy of Eli Lilly’s retatrutide has garnered attention within the medical community. Michael Weintraub, an endocrinologist at NYU Langone Health, described it as the “most effective anti-obesity med to date” in a post on Twitter. It is worth mentioning that the company’s other obesity drug, Mounjaro, which is approved for type 2 diabetes, has helped patients achieve weight loss of up to 21% in clinical trials.
In comparison, Novo Nordisk’s Wegovy, which is cleared for weight loss, has shown up to 15% weight loss in trials. Similar to Wegovy and Mounjaro, retatrutide is administered through a weekly injection and works by altering patients’ eating habits and reducing appetite, mimicking certain hormones in the gut.
However, retatrutide distinguishes itself by mimicking three different hunger-regulating hormones: GLP-1, GIP, and glucagon. This multi-hormonal approach appears to have more potent effects on appetite and food satisfaction, setting it apart from its counterparts.
In conclusion, Eli Lilly and Company’s retatrutide has demonstrated exceptional potential in the treatment of obesity. These groundbreaking results in the mid-stage clinical trial position it as a frontrunner in the pursuit of effective anti-obesity medications.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
